Physician profile
Truc Ta
NPI 1114459831
$18,759.56
in general payments reported to CMS, 2019-2025
21 companies · $14K in 2025
The $14K reported for 2025 was more than what 93% of Vascular Surgery providers received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,344 · 2024: $1,976 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $5,907 · Grant: $1,500 · Long Term Medical Supply Or Device Loan: $561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,792.40 |
| Travel and Lodging | $5,906.55 |
| Grant | $1,500.00 |
| Long Term Medical Supply Or Device Loan | $560.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,456.24 | 2025 | Ekosonic, General - Therapies, Eluvia |
| Medtronic, INC. | $3,920.30 | 2024-2025 | Valiant Captivia, Endurant Iis, Abre |
| Penumbra, INC. | $3,631.29 | 2023-2025 | Indigo System, Penumbra System |
| Lemaitre Vascular, INC. | $1,148.95 | 2023-2025 | Artegraft Vascular Graft, Hydro Lemaitre Valvulotome, Trivex System |
| Integra Lifesciences Corporation | $988.17 | 2025 | Integra, Cytal, Integra Dermal Regeneration Template |
| W. L. Gore & Associates, INC. | $858.69 | 2023-2025 | Gore Tag Thoracic Branch Endoprosthesis, Excluder Conformable Aaa Endoprosthesis With Active Control, Gore Viabahn Vbx Balloon Expandable Endo |
| Endologix LLC | $648.81 | 2023-2024 | Alto Abdominal Stent Graft System, Endocross Device, Torus Stent Graft System |
| Cook Medical LLC | $617.83 | 2023-2025 | Zenith Spiral-Z, Zilver Ptx, Zilver Vena |
| Organogenesis INC. | $560.62 | 2025 | Puraply Wound Matrix, Apligraf, Affinity |
| Bolton Medical INC | $386.13 | 2023-2025 | Treo Abdominal Stent-Graft System |
| Terumo Medical Corporation | $385.48 | 2023-2024 | Metacross Otw, Azur Cx Detachable, Glidesheath Slender |
| Abbott Laboratories | $289.08 | 2025 | Diamondback Peripheral, Esprit |
| Davol INC. | $223.54 | 2025 | Surgiphor, Arista |
| Route 92 Medical, INC. | $146.34 | 2025 | |
| Silk Road Medical, INC. | $139.77 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $106.87 | 2023 | Diamondback Peripheral |
| Tactile Systems Technology INC | $94.56 | 2024-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Shockwave Medical, INC | $83.30 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Becton, Dickinson and Company | $35.38 | 2024-2025 | Venovo, Covera |
| Philips North America LLC | $19.56 | 2024 | (Br5) Peripheral Ivus |
| Janssen Pharmaceuticals, INC | $18.65 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Truc Ta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.